In 2017 the European Haemophilia Consortium (EHC) received funding from the below income sources. The accounts of the EHC are audited by an external auditor and approved by its members during its Annual General Assembly.

 


EHC Funding 2017 - Industry versus non-industry funding

Source of incomeAmount in €% of the total income
Non-industry517,00731%
Industry1,147,32669%
Highest industry contribution210,98513%

EHC non-industry funding - 2017

Funding source Amount in €% of the total income
EHC membership and other fees16,0071%
EHC Conference income and conference-related fees199,00012%
Volunteer (non-remunerated) contributions302,00018%
Subtotal517,00731%

EHC industry-related funding - 2017

Funding sourceAmount in €% of total income
Alnylam112,5007
Baxalta125,0008
Bayer40,0002
Biotest17,5001
BioMarin30,0002
CSL Behring40,0002
Kedrion7,5000
MSD7,5000
Novo Nordisk70,0004
Opticom5230
Pfizer140,0008
PPTA4,0080
Roche140,0008
Sanofi-Genzyme3,0130
Shire195,00012
Sobi210,98513
UniQure3,7170
Subtotal1,147,32669